608 Shares in Cencora, Inc. (NYSE:COR) Acquired by Whipplewood Advisors LLC

Whipplewood Advisors LLC purchased a new position in Cencora, Inc. (NYSE:COR) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 608 shares of the company’s stock, valued at approximately $137,000.

Several other institutional investors have also modified their holdings of the stock. Oregon Public Employees Retirement Fund lifted its position in shares of Cencora by 0.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 15,051 shares of the company’s stock worth $3,382,000 after buying an additional 120 shares during the last quarter. Advisor OS LLC lifted its position in shares of Cencora by 55.8% during the 4th quarter. Advisor OS LLC now owns 2,243 shares of the company’s stock worth $504,000 after buying an additional 803 shares during the last quarter. FourThought Financial Partners LLC purchased a new stake in shares of Cencora during the 4th quarter worth approximately $215,000. Quartz Partners LLC lifted its position in shares of Cencora by 10.4% during the 4th quarter. Quartz Partners LLC now owns 8,853 shares of the company’s stock worth $1,989,000 after buying an additional 831 shares during the last quarter. Finally, Edge Capital Group LLC purchased a new stake in shares of Cencora during the 4th quarter worth approximately $2,832,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $248.71 on Friday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market capitalization of $48.23 billion, a P/E ratio of 35.38, a P/E/G ratio of 1.31 and a beta of 0.49. The company’s fifty day moving average is $240.74 and its two-hundred day moving average is $237.66. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $262.26.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.88%. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This represents a 24.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the subject of several recent analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Wells Fargo & Company lifted their target price on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. Barclays lifted their target price on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Evercore ISI lifted their target price on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Finally, Mizuho initiated coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.